QT-Cab: An Open-Label Study to Investigate the Effect of Cabazitaxel on the QTc Interval in Cancer Patients.

Trial Profile

QT-Cab: An Open-Label Study to Investigate the Effect of Cabazitaxel on the QTc Interval in Cancer Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2014

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms QT-Cab
  • Sponsors Sanofi
  • Most Recent Events

    • 15 Dec 2011 Additional locations identified as reported by ClinicalTrials.gov.
    • 15 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top